Moreover, combining the TrkA inhibitor CEP‐751 or CEP‐701 with androgen ablation was much more effective in treating prostate carcinoma in vivo than any of these regimens alone (George et al., 1999). This evidence concerns the gene NTRK1 and prostate carcinoma.